Researchers Detect Distinguishable Number of HER2-Low Cases Among Patients With Advanced Gastric Cancer

Article

The findings, according to a group of researchers, warrant the development of treatments that attack HER2-low advanced gastric cancer.

HER2-low advanced gastric cancer was discernable enough from HER2-negative and positive disease among a group of patients to justify the development of future treatment options for that patient subgroup, according to data from a single-institution study presented at the 2022 Gastrointestinal Cancers Symposium.

Overall, 21% of patients had HER2-low inoperable or recurrent advanced gastric cancer, and had immediately identifiable clinicopathological features in sex, histology, and metastatic site serum levels between those with HER2-negative and HER2-positive disease.

The aim of the retrospective analysis was to determine if HER2-low in gastric cancer can be distinguishable from HER2-positive or HER2-negative disease. Between 2011 and 2018, 750 patients with advanced gastric cancer were treated with fluoropyrimidine and platinum-containing chemotherapy. For this analysis, the researchers excluded 16 patients because a lack of available data on HER2 or FISH testing .

As a result, the study authors reviewed the findings from 734 patients, of which 410 had HER2-negative disease, 154 were HER2-low, and 170 had HER2-positive disease. The investigators defined HER2 disease as the following: HER2-negative with an immunohistochemistry (IHC) score of 0; HER2-low with IHC 1+ or 2+; and HER2-positive with IHC of 2+ or 3+. The data cutoff was August 2022.

The median age in the HER2-negative group was 64, 63 in HER2-low, and 64 in HER2-positive, with a majority of patients being male across all 3 groups (P = .193). The stomach was the most common location of the primary tumor with others including esophagogastric junction or the cardia (P = .029), with most being metastatic upon diagnosis (P = .001).

Most patients did not receive a gastrectomy prior to treatment (P = .008), and it was common for patients to have 2 or more metastases (P = .448).

The metastatic sites were split between either the liver (18.3% vs 24.8% vs 46.5%), distant lymph node (29.5% vs 37.0% vs 37.6%), or peritoneum (56.3% vs 44.8% vs 21.8%) in patients with HER2-negative, HER2-low, or HER2-positive disease, respectively.

The median overall survival among the HER2-negative group was 15.7 months (95% CI, 14.2-17.3), 15.7 months for patients with HER2-low disease (HR, 1.01; 95% CI, 0.82-1.23; P = .843), and 21.7 months (95% CI, 17.1-24.7) for those with HER2-positive advanced gastric cancer (HR, 0.73; 95% CI, 0.59-0.89; P = .002).

Progression-free survival (PFS) was evaluated if patients received subsequent chemotherapies. In those receiving taxane therapy, the PFS was 3.3 months, 3.5 months, and 4.1 months, across all arms respectively. The PFS for the 3 groups receiving irinotecan was 2.6 months, 2.4 months, and 2.5 months. For those receiving nivolumab (Opdivo), the PFS was 1.9 months, 2.1 months, and 2.7 months. Across all 3 regimens, there was no statistical difference in PFS.

To be eligible for the retrospective analysis, patients must have been aged 18 years or older, had histologically confirmed adenocarcinoma of the stomach or esophagogastric junction, and have had previously been untreated, inoperable, or recurrent advanced disease. Additionally, patients must have been treated with a platinum-containing regimen in the first-line setting and have confirmed HER2 status.

Exclusion criteria included having been previously treated at another hospital or being recurrent 6 months or more after the last therapy treatment.

The investigators concluded that the findings of the analysis confirm that the development of an effective treatment targeting HER2-low advanced gastric cancer is warranted.

Reference

Nakayama I, Takahari D, Chin K, et al. Clinicopathological features of HER2-low expressed advanced gastric cancers. J Clin Oncol. 2023; 41(suppl 4):459. doi:10.1200/JCO.2023.41.3_suppl.459

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content